May 17, 2020

Fitbit acquires clinical coaching platform Twine Health

Catherine Sturman
3 min
healthcare acquisition (Getty Images)
Leading wearables brand Fitbit is set to acquire Boston start up Twine Health for an undisclosed figure. The Twine Health Team will joinFitbitas part of...

Leading wearables brand Fitbit is set to acquire Boston start up Twine Health for an undisclosed figure. The Twine Health Team will join Fitbit as part of its Health Solutions group, with the deal set to close at the end of Q1 2018.

An innovative, health coaching platform, Twine Health works to enhance clinical services through the use of its coaching platform, empowering people to seek better health outcomes and lower healthcare costs.

A HIPAA-compliant connected health platform, Twine Health delivers a user-friendly experience to support people with long term health conditions, and provide guidance in providing guidance surrounding everyday wellbeing, collaborating with care teams, healthcare providers and any other individual or organisation involved in a patient’s care.

The Twine Health platform has developed a scalable approach to health coaching, allowing a single coach to work with a large number of patients, driving efficiencies while helping more people reach their goals.

The partnership will also enable Fitbit to further its reach into the healthcare industry, where it is increasingly competing with tech giants such as Amazon and Apple. Additionally, Fitbit remains as one of the companies taking part in the FDA program to bring new health and apps and technologies to the market.

Nonetheless, its recent acquisition will enable Fitbit to further tailor its service offerings towards the implementation of exceptional health plans and health systems, whilst creating opportunities to increase subscription-based revenue.

Long term, Fitbit will extend the benefits of the Twine platform to over 25 million users.

Founded in 2013, Twine Health has developed its approach based on years of behaviour change and clinical research done at the MIT Media Lab, the company has stated in a press release.

See also

Using a combination of artificial intelligence-driven insights and human interaction to generate positive health outcomes, it has automated parts of the coaching process and freed up time for more personalised care.

Randomised controlled trials conducted by world-renowned facilities including Massachusetts General Hospital and the Joslin Diabetes Center found that the foundational behaviour changes and principles behind Twine Health’s technology helped drive statistically significant improvements in both diabetes and hypertension management.

“Twine Health has delivered powerful results for patients with long term conditions such as diabetes and hypertension – two key focus areas for Fitbit, which together affect approximately 105 million people in the US alone,” explained James Park, co-founder and CEO of Fitbit.

“When combined with our decade-plus experience of empowering millions of consumers to take control of their health and wellness, we believe we can help build stronger connections between people and their care teams by removing some of the most difficult barriers to behaviour change,”

“Together, we can help healthcare providers better support patients beyond the walls of the clinical environment, which can lead to better health outcomes and ultimately, lower medical costs.”

 “We built Twine Health with the goal of putting people back at the centre of their care, helping them take ownership of their health actions and outcomes with the continuous support of both clinicians and loved ones,” explained Dr Moore, Twine Health’s co-founder and CEO.

“Technology has a profound opportunity to facilitate this shift in behaviour and give people the coaching they need to overcome the challenges that arise in daily life.”

“That potential becomes even more compelling when combined with Fitbit, whose brand and ability to engage and motivate a diverse range of consumers is incredibly powerful. Together, we can build a complete experience to optimise health at scale, across the full spectrum from prevention to disease management.”

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article